Absorption, metabolism, and excretion of 14C-labeled Tapentadol HCl in healthy male subjects

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 32, Issue 3, 2007, Pages 163-169

  Terlinden, Rolf ^a   Ossig, Joachim ^a   Fliegert, Frank ^a   Lange, Claudia ^a   Göhler, Karin ^a  

^a GRÜNENTHAL GMBH   (Germany)

Author keywords

Absorption; Analgesic; Excretion; Metabolism; Tapentadol

Indexed keywords

ANALGESIC AGENT; CARBON 14; CARBON DIOXIDE; DRUG METABOLITE; TAPENTADOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG METABOLISM; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EYE IRRITATION; FECES; HUMAN; KIDNEY; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; URINARY EXCRETION; URINE; VERTIGO; VITAL SIGN;

EID: 36549023069     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190478     Document Type: Article

References (21)

1. Weber H., Hallman C., Steup A. et al. (2006): Efficacy and safety of tapentadol HCl in patients with pain after bunionectomy. J. Pain, 7(suppl 1), S3. Abstract 312.
2. Kleinert R., Hallmann C., Steup A., Black P., Goldberg J., Desjardins P. (2006): Efficacy of a single dose of tapentadol HCl for analgesia after third molar surgery. J. Pain, 7(suppl 1), S44. Abstract 773.
3. Terlinden R., Ossig J., Fliegert F., Gohler K. (2006): Pharmacokinetics, excretion, and metabolism of tapentadol HCl, a novel centrally acting analgesic, in healthy subjects. J. Pain, 7(suppl 1), S26. Abstract 689.
4. Armstrong S.C., Cozza K.L. (2003): Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II. Psychosomatics, 44, 515-520.
5. Lugo R.A., Satterfield K.L., Kern S.E. (2005): Pharmacokinetics of methadone. J. Pain Palliat. Care Pharmacother., 19, 13-24.
6. Bruce R.D., Altice F.L., Gourevitch M.N., Friedland G.H. (2006): Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J. Acquir. Immune. Defic. Syndr., 41, 563-572.
7. Hollenberg P.F. (2002): Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab. Rev., 34, 17-35.
8. Ito K., Iwatsubo T., Kanamitsu S., Ueda K., Suzuki H., Sugiyama Y. (1998): Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol. Rev., 50, 387-412.
9. Bjornsson T.D., Callaghan J.T., Einolf H.J. et al. (2003): The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos., 31, 815-832.
10. Williams J.A., Hyland R., Jones B.C. et al. (2004): Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos., 32, 1201-1208.
11. Boase S., Miners J.O. (2002): In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br. J. Clin. Pharmacol., 54, 493-503.
12. Lin J.H., Wong B.K. (2002): Complexities of glucuronidation affecting in vitro in vivo extrapolation. Curr. Drug Metab., 3, 623-646.
13. Ventafridda V., Bianchi M., Ripamonti C. et al. (1990): Studies on the effects of antidepressant drugs on the antinociceptive action of morphine and on plasma morphine in rat and man. Pain, 43, 155-162.
14. Boxenbaum H. (1999): Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. J. Pharm. Pharm. Sci., 2, 47-52.
15. Heiskanen T., Olkkola K.T., Kalso E. (1998): Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin. Pharmacol. Ther., 64, 603-611.
16. Lugo R.A., Kern S.E. (2004): The pharmacokinetics of oxycodone. J. Pain Palliat. Care Pharmacother., 18, 17-30.
17. Lugo RA, Kern SE (2002): Clinical pharmacokinetics of morphine. J. Pain Palliat. Care Pharmacother, 16, 5-18.
18. 1 serum levels with antinociceptive activity in mice. Naunyn Schmiedebergs Arch. Pharmacol., 343 (Suppl.), R9. Abstr. 36.
19. Raffa R.B., Friderichs E., Reimann W. et al. (1993): Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J. Pharmacol. Exp. Ther., 267, 331-340.
20. Poulsen L., Arendt-Nielsen L., Brosen K., Sindrup S.H. (1996): The hypoalgesic effect of tramadol in relation to CYP2D6. Clin. Pharmacol Ther., 60, 636-644.
21. Desmeules J., Gascon M.P., Dayer P., Magistris M. (1991): Impact of environmental and genetic factors on codeine analgesia. Eur. J. Clin. Pharmacol., 41, 23-26.